This presentation survcys modern concepts for drug screening as they havc emerged from current neurochemical research. Among others, the concept of multiple forms of MAO and phosphodiesterase has rcvolutionized the approach to drug screening of compounds that change neuronal function through inhibition ofthese enzymes. Neurochemical progress has opcned new vistas and has given indications on how to screen MAO inhibitors for maximum efficacy while avoiding potential side effccts. The finding that drugs acting on postsynaptic receptors can now be screened in preparations with receptors madesupersensitive by dcnervation provides another new model, madc possible by the discovery that 6·0H·dopamine and 6·hydroxyserotonin can lesion neurons selectively. The use ofturnover rate measurements in association with other tests can contribute valuable information on the anatomical site of action of drugs. These tests have a great predictive value if conducted with quantitative criticism of dose-response relations.
INTRODUCTION
N urneraus examples can be marshalled to provide evidence that serendipity has played a major role in the discovery of the most important drugs introduced in neuropsychiatry during the last 25 years. However, sporadic exceptions exist. One of them is the successful use of L-dopa as a symptomatic remedy for Parkinson's disease. Undoubtedly, L-dopa would not have been tested without the important discovery made by Ehringer and Hornykiewicz 1 that a decrease of dopamine concentration in striatum is a symptom of Parkinson's disease. This finding might not have promoted the use of L-dopa as a potential remedy in Parkinsonism 2 bad Blashko 3 not shown that this amino acid is involved in the biosynthesis ofendogenaus catecholamines. When L-dopa was first tested in Parkinsonism it was also known that parenteral administration of L-dopa increases the brain concentrations of dopamine in normal animals and in animals treated with reserpine 4 • A nurober of drugs presently used in neuropsychiatry were developed 439 E. COSTA as a result of elaborate programmes of chemical synthcsis. Many such programmes evolved from evidence indicating that a given molccular group was responsible for the therapeutic effcct of existing remedies. In thcse attempts such molecular groups wcre introduced into appropriate chemical structures in order to produce new compounds with a better therapeutic index. Perhaps in these chemical manipulations compounds with unexpected therapeutic propertics werc obtained, but thcse properties were not detected because the pharmacological screening of the new molecules was designed to reveal and cvaluate the properties of the drug used as a prototypc. Thus, our Iack ofingenuity in formulating screening procedures has confincd many potentially useful drugs to the shelves of drug firms. I am certain that each one of us could mention an appropriate example to support this statement.
In fact, a nurober of drugs havc acquired a proper thcrapeutic indication many years after their synthesis. Often this thcrapcutic indication is different from that originally intended when these drugs were synthcsized. A case in point is cr-methyl-dopa which was originally synthesized as a potential hypertensive drug, but when tested failed to cause hypertension. Sevcral years later, cr-methyl-dopa was tested clinically as a hypotensive agent because appropriate screening tests 5 had shown that this drug could lower the concentrations of norepinephrine in centrat and peripheral noradrenergic neurons 6 • Apparently, this was a lucky rationalization for cr-methyl-dopa is still used as a hypotensive agent. With these considerations in mind, I have decided to talk to you about certain fundamental principles that areernerging from current neurochemical research. With the prog~~ss ~f our ~nderstand.ing of. ~rain biochemistry, these concepts are acqmnng mcreasmg value m devtsmg drug screening 440 DRUG SCREENING IN NEUROPSYCHOPHARMACOLOGY procedures which help us to detect the potential usefulncss of new neuropsychiatric drugs. Table 1 summarizes some regulatory mechanisms of neuronal function which are possible sites for drug action: the receptor, the nerve terminal membrane, and various intraneuronal sites. Each ofthesc sites can participate in short-and long-term regulation of neuronal function: the present report will be mainly concemed with drug action on sites involved in short tcrm regulation of neuronal function. This decision does not imply that long term regulation should not concern pharmacologists: rather it indicates that our knowledge is still too fragmentary to be cxpressed in suitable models for drug screening.
THE CONCEPT OF POSTSYNAPTIC RECEPTOR IN DRUG DEVELOPMENT
The discovery that 3',5'-cyclic AMP catalyzes the enzymatic phosphorylation of proteins by kinases 7 and the realization that the function of membrane-bound adenylate cyclase can be regulated by catecholamines 8 , including norepinephrine (NE) 9 and dopamine (DM) 10 , have prompted a drastic revision in the conceptualization of the biochemistry of postsynaptic receptors. Catecholamines and, perhaps, other putative transmitters, activate the membrane-bound adenylate (or guanylate) cyclase increasing the formation of cyclic nucleotides from ATP and GTP. We do not understand how these nucleotides can elude inactivation by phosphodiesterase, a soluble enzyme prescnt in cytoplasm, to convey intracellularly the message brought to thc cell surface by the transmitter. Howevcr, the 3',5'-cyclic AMP (termed second messenger) and the intracellular mechanisms that make its action possible, should now be considcred as an important site for the action of drugs that mirnie the cffects of certain transmitters. Since there are different molecular forms of phosphodiesterases 11 , which may be cell specific 12 and possess different sensitivity toward drug inhibition, the ubiquitous adenylate cyclase system may be manipulated pharmacologically with some degrcc of selectivity. Probably the postsynaptic receptor uses the adenylate cyclase as a transducer to transform the synaptic event into a message for the mechanisms that control protein synthesis in the postsynaptic cell.
Receptor stimulants (i) Direct stimulants
The studies of cholinergic and noradrenergic peripheral neurons have pioneered the present understanding of synaptology by proving that neurons control the cells they innervate by secreting appropriate chemical mediators at synapses. The secretion of these transmitters enables neurons either to initiate a variety of responses in the postsynaptic cell (contraction of striated muscles, secretion of glands, ctc.) or to modulate the frequency of spontaneaus rhythmical activities in cells endowed with such a property.
More than thirty years ago, as a corollary to these studies, Dale formulated a basic axiom concerning the chemical nature of synaptic transmitters. This axiom, which is still widely accepted on its intrinsic merit, postulates that 441 each neuron synthesizes, stores, and secretes one and only one type of transmitter. This concept coupled with the uniformity of responses elicited by a given transmitter in a given peripheral tissue (contraction of striate muscles, secretion of salivary glands, etc.) has contributed to,.the expectation that, in the brain, drugs which mirnie a given transmitter elicit a defined functional and behavioural response. Of course, when such drugs are administered systemically, they elicit complex responses due to stimulation of the numerous specific receptors located in neuronal systems involved in the control of diversified neuronal mechanisms. Such unexpected complexities of drug effects are usually referred to as side effects of the drug. This is a misnomer. These side effects are not collateral and unexpected effects of the drug, but they reflect the stimulation of identical receptors involved in other brain functions. As an example, we may take chlorpromazine and other neuroleptics chemically related to chlorpromazine. It is presently believed that these drugs elicit their action because they occupy dopaminergic receptors where they preven t the action of dopamine 1 3 • I t is, therefore, not surprising that after prolonged administration, the neuroleptic action is contaminated by extrapyramidal disturbances because dopaminergic receptors identical to those necessary for the neuroleptic action are involved in the regulation of extrapyramidal function. Similar considerations apply to the emesis occurring du ring the administration of L-dopa to Parkinsonian patients: this reflects the involvement of dopamine receptors in the function ofthe myelencephalic trigger zone, a site of convergence for neuronal activity involved in the control of vomiting. To recapitulate this point, Iet us consider the data reported in Table 2 which illustrates the projection of noradrenergic, dopaminergic, and serotonergic neurons to various brain structures. This Table includes only three putative transmitters but there is reason to believe that other neuronal systems may display an equally diffuse innervation. This suggests that many 442 different brain structures are regulated by the same transmitter. Electrophysiological studies on neuronal responses to the application of various transmitters in the vicinity of neuronal cell bodies show that the application of a given putative transmitter elicits very similar responses in various neuronal populations 14 of brain. Therefore, one can summarize, that the effects on the excitability of the neuronal membrane are not different.
In conclusion, a selectivity of neurological and behavioural responses is at best the exception in the pharmacological profile of drugs which directly activate the postsynaptic receptors of a given neurotransmitteL Perhaps when pathological conditions resembling surgical denervation change receptor function, its susceptibility to the action of drugs that mirnie the transmitter can be enhanced (denervation supersensitivity). This enhancement results in a certain degree of selectivity of the drug response in the In rats the monolateral injection of 6-hydroxydopamine 15 in the substantia nigra selectively destroys the cell body of the dopaminergic neurons of the nigro-striatal pathway ( Table 2 ). These rats either exhibit circling toward the lesioned side or remain immobile. The injection of drugs that mirnie the effects of dopamine on striatal receptors causes intense circling away from the lesioned side. With this preparation, one can have a realistic appreciation ofthe therapeutic index ofthe drug in conditions ofreceptor supersensitivity. Similar screening models can be devised for noradrenergic receptors which can be denervated by injections of 6-hydroxydopamine in appropriate brain regions and for serotonergic receptors which can be denervated by injections of6-hydroxyserotonin (6-HS) 16 • This drug injected intracisternally destroys serotonergic nerve terminals of spinal cord selectively (Table 3) .
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Since serotonergic function is involved in spinal rcflexcs, it may turn out that pretreatment with 6-HS may be a suitable model to test drugs that directly stimulate serotonergic receptors.
(ii) Indirect stimulants.
The term 'indirect stimulation of postsynaptic receptors' dcscribes the effect of drugs which increase the amount of transmitter reaching postsynaptic receptors. These drugs may interfere with various mechanisms regulating the release from nerve endings of thc transmittcr. These mechanisms are located either in the membrane ofthe ner.ve terminal or extra neuro-, nally in the vicinity of the postsynaptic receptors. Here we shall consider only those mechanisms which are extraneuronally located and are enzymatic in nature. These mechanisms have a particular importance for the cholinergic mechanism and intluence the noradrenergic function to a much smaller extent. The two enzymes involved arc termed acetylcholinesterase and catecholamine-0-methyltransferase. Several inhibitors of cholinesterascs have been developed. Due to the diffuse distribution of brain cholinergiC receptors, the use of these drugs is plagued by a great number of collateral effects. A certain degree of specificity can be conferred on this inhibitory effect by altering the physicochemical properties of the drug and these molecules can thus bc excluded from the brain. However, when they are used to modify abnormalities of cholinergic receptor functions, the anticholinesterases exhibit a limited specificity.
In conclusion, the experience acquired on the indirect stimulation of synaptic receptors by inhibitors of the enzymes tha t inactivate the transmitter does not predict encouraging prospects for future drug developments.
Receptor inhibitors
Inhibition of postsynaptic receptors may Iack an appropriate selectivity for reasons similar to those mentioned earlier in this report with regard to stimulation of postsynaptic receptors. Since the transmitter concentrations at receptors is a factor that controls the affinity constant of rcceptor blockers that act competitively, rates of transmitter release should be considered as a variable in the efficacy ofthese drugs. To assess this variable, the potency of these inhibitors should be tested in experimental conditions where the spontaneaus rates of transmitter releasc from pertinent nerve terminals are different. During adaptation to cold exposure, the activity of certain central and peripheral catecholaminergic neurons is increased. This increase can be estimated in vivo by measuring the turnover rate of the transmitter involved. Using this approach, we have estimated NE and DM turnover rate in various tissues or brain regions of rats kept at two different environmental temperatures. The data of Table 4 show that the turnover rate of heart and cerebellar NE is increased by cold exposure. From this finding one can infer that the central and peripheral catecholaminergic neurons do not respond to stressful Situations with a diffuse and generalized increase of activity. Cold exposure may therefore be a suitable screening device to estimate the efficacy of postsynaptic receptor blockers in relation to various rates of neuronal activity. Table 4 . Turnover rate of dopamine (DM) and norepinephrine (NE) in various tissues of rats kept at 20"C and 4°C nmolc g- 
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* k significantly different from that of rats kept at 20"C. Rats were kept at thc tndicated tcmpcrature for 14 hours beforc mcasuring turnovcr rate of NE by an isotopic mcthod (pulse injection of 3.5-3 H tyrosinc).
In vivo hlockade of postsynaptic reccptors is associatcd with an increased turnover rate of the transmitter stored in the nerve terminals facmg tne postsynaptic reccptor that is blocked. This increasc has been explained by scvcral mechanisms: (a) collateral neuronal loops emanating from the cell inhibitcd by the blocker; (b) blockade of presynaptic reccptors which are important to regulate transmitter release; (c) interference with reuptake mechanisms.
Postsynaptic receptors and second messenger as a site for drug action
Various schemes have been presented to depict how the message brought about by the action of the transmitter on receptors in the postsynaptic membrane is transferred to the pertinent intraccllular compartments for further elaboration and transaction. Experiments performed with pineal gland 9 , cervical sympathetic ganglia 10 , and adrenal medulla 16 have clearly indicatcd that the stimulation of postsynaptic receptors may be linked with a changc in the membrane-bound adenyl cyclase activity of postsynaptic cclls. As first suggested by Sutherland and co-workers 17 , the adenyl cyclase associated with postsynaptic rcceptors may be viewed as formed by a regulatory and catalytic unit; the transmitter would bind to the regulatory unit and by this binding alter the basic rate of intracellular formation of 3',5' -cyclic adenosinc monophosphate (cAMP). This nucleotide is believed to activate various enzymes intracellularly; since it mediates the effects of hormones and transmitter, it has been termed 'second messenger'. As an example ofthis interaction, we report in Table 5 the effect of carbamylcholine injected into monolaterally splanchnicotomized rats on the cAMP concentration of normal and denervated adrenal medulla. These data show that this parasympathomimetic increases the concentration of cAMP in intact and splanchnicotomized medulla. Note the rapid rate of accumulation of cAMP at the time approach peak effect; this rate assures that an amount of cAMP equal to the steady state concentration of the nucleotide accumulates in the tissue in about one minute. Carbamylcholine, in vifro, does not reduce the activity of phosphodiesterase, the enzyme that catabolizes cAMP. Therefore, one must assume that under the stimulatory action of carbamyl-445 choline, the turnover time of cAMP in adrenal medulla, it is even greater than that mentioned above because the nucleotide is continually metabolized while it accumulates in the medulla as a result of carbamylcholine action. Although the catabolic rate of medullary cAMP cannot be estimated precisely, it seems conceivable that it should be at least equal to the rate of cAMP accumulation elicited by aminophylline, a drug that inhibits phosphodiesterase. To estimate this rate, we have measured the cAMP accumulation in intact and splanchnicotomized adrenal medulla of rats receiving 200 llmoles kg-1 i.p. of aminophylline. These data are reported in Table 5 and show that the rate of accumulation is greater in intact than in splanchnicotomized adrenal medulla. Since we have shown that aminophylline inhibits equally weil the phosphodiesterase of normal and denervated adrenal medulla, we conclude that the afferent neurons to adrenal medulla regulate cAMP turnover rate by acting on adenyl cyclase. If, as will be shown later, cAMP plays a regulatory role in the elaboration of synaptic activity impinging upon the membrane of chromaffine cells, then one might change the response of the postsynaptic cells by injecting drugs that can modulate cAMP metabolism. An obvious site for this regulation is the phosphodiesterase. U zunov and Weiss 11 reported that the soluble supernatant fraction of rat cerebellar homogenates contains various enzyme proteins with phosphodiesterase activity which can be separated by electrophoresis on a preparative polacrylamide gel column. Analyzing successive fractions of the column eluate for phosphodiesterase activity they found five distinct peaks of enzymatic activity designated I to V according to the order in which they emerged from the column. They also detected a discrete fraction containing a potent phosphodiesterase activator. This protein increases the activity of peak li about fourfold and that of peak V about two-fold, whereas the activities ofpeaks I, III, and IV were unaffected by the activator. Ca 2 + increased the activity ofpeak li only. The five peaks 446 
of phosphodiesterase also bad markedly different stabilities, peaks 111 and V being the least stable (tt of 1 day when stored at 4°C).
In other studies, Uzunov and collaborators 12 established that in celJ cultures on neuroblastoma, only peak lii was present. Thus, the enzyme associated with peak lll is ofparticular interest in screening neuropsychiatric drugs because it appears to reside in neurons. Sincc the adenylate cyclase system is ubiquitous and of physiological importancc in various cells, the possibility of interfering selectively with neuronal phosphodiesterase appears to be an essential prerequisite for drug action in central nervaus system. Drs. Strada and Suria have initiated such an exploration and their preliminary results are reported in Table 6 .
The data reported in Table 6 show that diazepam is slightly more effective than aminophylline in inhibiting the phosphodicsterase present in neurons (peak lll). Moreover, if the activity of diazepam is comparcd with that of chlordiazepoxide, thc former appears to be five-fold more active than thc latter. Not only are these benzodiazepines structurally related to diphenylhydantoin, but they share its anticonvulsant actio~. The data rcported in Table 6 show that diphenylhydantoin is weaker than either benzodiazcpine as a phosphodiestcrase inhibitor. This finding may be relevant to cxplain the anticonvulsant activity of diphenylhydantoin and benzodiazepines because an action on the Purkin je cells of ccrebellum appears tobe important for their anticonvulsant effectl 8 • 19 . It may bc pertinent to note that NE injected microiontophoretically hyperpolarizes thc Purkinje cells and this action appears to be mediated through cAMP 20 . It is also of intcrest that the phosphodiesterase inhibitory potencies of these three compounds rank in a sequence similar to their anticonvulsant activity.
Trans-synaptically controlled long-term regulation of neuronal function
Two main lines of evidence have contributed to our present understanding ofthe long-term regulation oftyrosine hydroxylase activity in the adrenal medulla. One was provided by Axelrod 21 by showing that tyrosine hydroxylase activity is regulated trans-synaptically, thc other by K vctnansky and collaborators 22 by showing that an injection of dibutyryl cyclic AMP restores the activity of tyrosine hydroxylase in hypophysectomized rats. Since afferent cholinergic nerves to the adrenal regulate medullary adenyl cyclase, we have investigated whether the prolonged increase of cyclic AMP in adrenal mcdulla elicited by aminophyBine (Table 5) , carbamylcholine (Tahle 5), and reserpine (Table 7) would be associated with a delayed increase of the tyrosine hydroxylase activity of adrenal medulla. To establish such a relationship, we have investigated whether drugs which promptly increase the concentration of medullary cAMP can after several hours increase the tyrosine hydroxylase activity of adrenal medulla. Tbc results of thcse experiments are reported in Table 7 .
These data show that the peak increasc in cAMP concentrations is attained in about 12 minutes but the increase of tyrosine hydroxylase activity occurs 10 to 14 hours after the drug injection. The data reported in Table 7 show that after injecting the various tyrosine hydroxylase inducers, accumulation of cAMP at its peak does not rank in parallel with the increase of tyrosine hydroxylase activity. However, the rate of cyclic AMP accumulation appears 448 DRUG SCREENING IN NEUROPSYCHOPHARMACOiOGY re]ated to the increase of tyrosine hydroxylase activity. We are presently investigating the sequence of biochemical events occurring in the time interval elapsing between accumulation of cAMP and the increase of tyrosine hydroxylase activity; we are now studying whether protein kinase activation and phosphorylation of acidic nuclear proteins and histones are among the events occurring in this time interval. In neurons, trans-synaptically mediated enzyme induction may be a physiological mechanism; accordingly, alteration of the trans-synaptic control of enzyme induction may cause neuronal pathology. ·; The maximal accumulation of c-AMP is attaincd in about 12 minutes aftcr drug injcction. Thc accumulation rate of c-AMP is calculatcd from c-AMP concentrations mcasurcd betwccn 6 and 12 minutcs after the injection.
Methods to estimate drug effects on nerve terminal function
In Table 1 I have listed several mechanisms located either on the nerve terminal membrane or intraneuronally, which are involved in the short-and long-term regulation of neuronal function. Some of these mechanisms can be easily tested in vitro in connection with drug screening. These include: (i) synthesis, (ii) catabolism, and (iii) uptake of transmitters.
( i) S ynthesis
Transmitter biosynthesis is sometimes regulated through a feedback control by product inhibition of the rate-limiting enzyme for the transmitter biosynthesis. Actually, of the three best known putative transmitters, only the biosynthesis of catecholamines is regulated through a product inhibition of tyrosine hydroxylase activity 25 • The details of such a negative feedback are not thoroughly understood. It is known that catecholamines inhibit tyrosine hydroxylase by interfering with the pteridin cofactor 26 , essential
for the function of this enzyme. Among the endogenaus catechols, the highest affinity for this regulatory mechanism is displayed by DM. Since this NE precursor is free in the cytosol of sympathetic nerves where tyrosine hydroxylase is also located, DM may play a physiological roJe in the in vivo control of tyrosine hydroxylase 27 • If an excessive production of tyrosine hydroxylase were to be a recognized pathological cause of noradrenergic nerve disfunction, one may attempt to correct this defect by administering drugs that mirnie the effect of DM or NE in the regulation of tyrosine hydroxylase activity, but not in their physiological action or in their binding properties to storage sites. Another approach to reduce excessive synthesis is to find inhibitors of pteridin reductase, the enzyme that maintains optimal concentrations of reduced pteridin cofactor
•
The regulation for serotonin and acetylcholine biosynthesis seems to depend on the availability of substrate for the hydroxylating and acetylating enzyme, respectively. Thus within Iimits, serotonin synthesis depends on the concentrations of tryptophan available while acetylcholine synthesis is regulated by the availability of choline at the site of synthesis. However, the mechanisms involved are only apparently similar; in the case of acetylcholine, due to the excess of choline acetyltransferase, short-term regulation depends on the retrieval of choline by the nerve terminals 29 • Since this choline is formed from the recently-released acetylcholine, the rate of choline uptake regulates acetylcholine synthesis and relates to that of neuronal activity. Also, in the case of brain serotonin biosynthesis, the enzymes involved are not saturated by their respective substrates. A vailability of substrates may also have a regulatory order. The regulation ofthe tryptophan availability at the sites of synthesis depends on the concentrations of frcelydiffusable plasmatic tryptophan. Since free tryptophan is in equilibrium with tryptophan ionically bound to plasma protein, it follows that any molecule that competes with tryptophan for its binding sites in plasma might alter serotonin synthesis in brain.lt remains tobe ascertained whether the increase of 5-HT synthesis elicited by excesses of tryptophan avai1ability has a functional significance.
The three types of regulation of transmitter biosynthesis describcd above are currently being studied in various laboratories; the outcomc of such experiments may be ofimportance for future development ofnew drug screening procedures.
(ii) Metabolism
The existence ofmultiple forms ofmonoamine oxidase (MAO) has received strong support by a nurober of recent reports 30 -32 • Johnston 31 has reported that clorgyline allows for the distinction of two forms of MAO in rat brain homogena~es, an enzyme. form termed Type A which is inhibited by Iow concentratwns of clorgyhne and an enzyme form designated as Type B which is relatively insensitive to these concentrations of clorgyline. The Type A enzyme is more effective than Type B enzyme in metabolizing serotonin while both enzymes are equally effective in metabolizing tyramine. Independent reports by Jarrot 33 and by Neffand Goridis 32 have shown that sympathetic nerves contain predominantly Type A MAO and that Type A 450 enzyme is very effective in metabolizing not only serotonin, but also norepinephrine and normetanephrine. Probably Type A enzymeisnot a single entity; the ratio of tyramine to serotonin metabolized by Type A enzyme varies from tissue to tissue. Type B enzyme preferentially deaminates benzylamine. Tryptamine and dopamine, like tyramine, are metabolized equally weil by both types of enzyme. This specificity of various forms of MAO toward certain substrates and their different sensitivity toward certain inhibitors opens new avenues for drug development in the field of MAO.
It is weil known that the ingestion offoods containing high concentrations of biogenic amines by individuals receiving MAO inhibitors evokes episodes which resemble the clinical picture of pheochromocytoma (transient hypertension, headache, palpitation, nausea, vomiting, etc.). These symptoms are due to high blood Ievels of biogenic amines which are not detoxified by the liver enzyme. With the discovery of selective inhibitors of Type A enzymes, it appears that one might influence metabolism of serotonin and norepinephrine in monoaminergic nerves which contain Type A enzyme without altering the destruction by Type B enzyme of liver of the amines absorbed from the intestine. The data reported in Table 8 show that the concentrations of clorgyline or Lilly 51641 requircd to block the metabolism of phenethylamine or tyramine are 600-and 300-fold greater than those required to inhibit 5-HT metabolism. In contrast, MAO inhibitors used clinically (pargyline and ttanylcypromine) inhibit the mctabolism of phenethylamine or tyramine better than that of 5-HT. Although the differencc in affinity for various substrates displayed by Lilly 51641 may not yet be sufficient to obtain a satisfactory therapeutic index, it is possible that compounds with a satisfactory therapeutic index may be developed following such an approach. Finally, I would like to draw attention to deprenyl, a MAO inhibitor developed by Knall and Magyar 34 which fails to potentiate and may antagonize the biological effects of tyramine. They also obtained a very flat dose response curve for the inhibition of tyramine mctabolism by this drug and a very prominent inhibitory activity toward benzylaminc. This peculiar relationship suggests that the antienzymatic properties of deprcnyl against various substrates shou1d be studied more thoroughly because in the light of present developments, its weak inhibitoty effect against tyramine should be considered an advantageaus property.
(iii) U ptake mechanisms
Nerveterminals in the brain possess specialized uptake mechanisms for a variety of putative neurotransmitters, such as dopamine, norepinephrine, serotonin, choline, y-aminobutyric acid, glutamic acid and glycine 35 • 36 . Kinetic studies have elucidated optimal conditions for nerve endings to accumulate selectively their specific transmitter. By separating with density gradient centrifugation the synaptosomes (pinchcd-offnerve endings present in brain homogenates), populations of brain neurons relatively uniform with regard to the transmitter content can be separated and their biochemical properties studied. With regard to drug screening, it is important to consider that inhibition of monoamine uptake is a possible mechanism of action for varibus neuropharmacological agents. lf a compound preferentially inhibits uptake of a transmitter, one usualJy infers that when this drug is injected into the animal, it will increase the time course of the transmitter-rcceptor interaction and will therefore prolang the duration ofthe rcceptor stimulation by the natural transmitter. Conceptually, this inference is acceptable, but it may not be practically verified because it implicitly assumes that a drug injected in vivo causes only one action. To verify whether blockade of uptake operates in vivo, one can integrate the results of in vitro measurements of uptake with turnover rate estimation of the transmitter in vivo.
6. Storage and release of transmitter as sites for drug action Acetylcholine 37 , catecholamine 38 , and serotonin 39 are storcd in nerve endings bound to synaptic vesicles. Nerve impulses release the transmitter by partial exocytosis 40 , whereby only part of the vesiclc content is ejected in the synaptic cleft. However, in this process not only the transmitter but 452 also enzyme proteins and other proteins contained in the synaptic vesicle reach the extracellular fluid 40 . Partial exocytosis brings the inside of each vesicle into contact with the extracellular fluid several times during its life cycle. Since during each exposure a proportion ofthe synaptic vesicles content is lost and since protein synthesis in nerve terminals is minimaland localized to the mitochondria, the participation of a given synaptic vesicle to successive partial exocytoses causes its reduction in size and its increase in electron density. Thus reduction in size expresses aging. This morphological counterpart of aging might explain the polymorphism exhibited by synaptic vesicles stored in a nerve terminal; the vesicles of small size and with dense core being the oldest members of the population of synaptic vesicles of a nerve terminal. Some authors have proposed that the smallest vesicles do not participate to exocytosis but still exchange their material with surrounding younger vesicles 40 .
The various mechanisms involved in the storage process arenot entirely understood; it is known that monoaminergic synaptic vesicles con tain A TP and transmitter in a fixed ratio 41 . The storage process is sensitive to drug action, reserpine being the prototype of drugs that inhibit amine storage irreversibly 42 . In fact, in animals receiving reserpine, storage is back to normal only after the population of synaptic vesicles is completely renovated43. Although it is conceivable that reserpine binds covalently to some constituents of the synaptic vesicle, the molecular nature of the reserpine receptor is not known. Moreover, the reserpine receptor is not a gcneralized receptor present in all synaptic vesicles. Presumably, the vesicles that store GABA and acetylcholine are not affected by reserpine.
In practice there are simple neurochemical tests that characterize a reserpine-like action. These are: measurement of tissue monoamine concentrations; measurements of the brain concentrations of NE and 5-HT acidic metabolites; estimations of monoamines uptake with and without MAO inhibitors; estimation of the uptake of an ct-methyl-monoamine; assay of RNA concentrations in the cell body of monoaminergic neurons 44 ; and measurement of the activity of enzymes involved in monoamine biosynthesis. During a reserpine-like action (a) the monoamine tissue concentrations are decreased for weeks; (b) in brain, the acidic metabolites of 5-HT and NE are increased because the amines are released intracellularly where they are metabolized by MAO; (c) the uptake ofNE appears impaired but it is normalized if the animals are injected with MAO inhibitors; (d) the uptake of the ct-amino analogue of NE is not impaired; (e) twenty-four hours after the injection ofa reserpine-like drug, the RNA concentrations in tissues containing noradrenergic cell borlies (sympathetic ganglia) are increased; this increase reflects formation of synaptic vesicles; and (f) the activity of the enzymes involved in the monoamine biosynthesis is normal. From the foregoing, it appcars that the long-lasting depletion of monoamines is insufficient to characterize a reserpine-like action. In fact the injection of cx-methyl monoamines (metaraminol, cx-methylnorepinephrine, etc.) can cause a long-lasting depletion of peripheral catecholamines 45 · 46 similar to that elicited by reserpine. These drugs are taken up by nerve endings and stored in synaptic vesicles where they replace the transmitter 4 7 . They can be released by nerve impulses and are retrieved in nerve endings during the 453 resting phase. If the amine replacing the transmitter has an intrinsic activity lower than that of the natural transmitter, then, when it is released on to receptors, it causes a reduced response. For these reasons, such an amine is often termed a 'false neurochemical transmitter'. Two analogues of dopamine and 5-HT: 6-0H-dopamine and 6-0H-serotonin, respectively, concentrate in the two types of neurons. These molecules display a high chemical reactivity. When these two drugs accumulate in nerve terminals by virtue of their chemical reactivity, they cause permanent darnage to the nerve endings 48 • Repairs to this darnage can occur several months later by axonal sprouting. The depletion of tissue catecholamines caused by 6-0H-dopamine can be differentiated from that elicited by a false transmitter because the effect of 6-0H-DM is associated with a marked decrease of the enzyme's activities that are involved in the biosynthesis of NE. Some drugs are taken up by monoaminergic nerves (guanethidine is taken up by adrenergic nerves), but they cannot be readily stored in synaptic vesicles 44 • When guanethidine or some related compounds are injected in chronically high doses, they can cause destruction of the adrenergic nerves.
7. Drug effects on monoamine tumover rate Figure 1 illustrates the present understanding of the processes involved in the release of catecholamines by nerve impulses. As shown in Figure 1 , turnover rate of monoamines proceeds at a variable rate regulated by a feedback control operating at the Ievel of the mixed function oxygenase. At rest, the amine uptake maintains the synaptic cleft free oftransmitter and thus plays a role in regulating the function of nerve terminals (Figure 1 ). When the depolarizing wave reaches the nerve terminal, Ca 2 + entry into the nerve terminal is facilitated. Simultaneously, by a phenomenon of partial exocytosis, the amine is released from the synaptic vesicle into the synaptic cleft. At the time of maximal amine release by exocytosis the amine uptake is virutally nonexistent This is also the time in which catecholamine concentrations in the synaptic cleft reach their peak. Perhaps by acting on a presynaptic regulatory receptor (R in Figure 1 ), the amine reduces the influx ofCa 2 + and terminates the exocytosis which appears tobe Ca 2 + -dependent. Although our understanding of the molecular mechanisms involved and their sequence is at best fragmentary, we can hypothesize that drugs may facilitate or reduce the rate of transmitter effiux from nerve terminals by interacting with the various processes outlined in Figure 1 . Drugs, by acting on the R receptor (Figure 1 ), may facilitate Ca 2 + influx, thus proionging the duration of exocytosis. Conversely, they may impair Ca 2 + influx and reduce the transmitter release. The receptor R depicted in Figure 1 is a regulatory site for the turnover rate of the transmitter which is susceptiblc to the action of drugs. These drug effects may be influenced by the nerve impulse activity. Therefore, drugs acting on the R receptor change the turnover rate of the transmitter to an extent which is related to nerve impulse activity. Other drugs may change the rate oftransmitter turnover because they prevent the physiological retrieval of the released transmitter. With blockage of reuptake, interaction of the amine with the presynaptic R receptor is facilitated. As a result, the effect of these drugs tends to be independent of the rate of nerve activity. A summary of current views is presented in Table 9 . 8. Methods to measure monoamine tumover rate Table 10 lists the methods that can be used to measure isotopically the turnover rate of 5-HT in brain and peripheral tissues. While the methods in (A) and (B) have been described in previous publications, method (C) was developed only recently 50 . In brief: (i) DM concentrations in noradrenergic nerves can be measured by multiple ion detection using gas chromatograph-mass spectrometry. To obtain gas chromatographic separation of DM, the perfluoropropionic derivative of the amine is obtained by reacting the amine with perfluoropropionic anhydride 51 • (ii) Dopa concentrations in caudate are measured fluorometrically as described in a previous publication 52 . Usually, wc, as weil as other authors, have measured turnever rate of 5-HT and NE from the change with time of the specific activity of the amino acid precursor at the rate-limiting step and that of the amine transmitter. Considering thc model of DM biosynthesis in the caudate: and SA Dopa = [Dopa J
(1)
Thc question now arises whether we can substitute SA TY for SA Dopa. lt is obvious that this substitution can be done if and only if SA TY = SA Dopa. This will be possible only if d SA Dopa = O dt only in this particular case can we write (4)
Therefore equation 4, which is the equation frequently used to calculate turnover rate of DM 53 is valid only for a short and specific time interval following the injection of 3 H-TY. In practice, this implies that in order to determine the turnover rate öfa transmitter we need data to plot a time curve of the specific activity of the transmitter itself and oftheimmediate precursor. However, it is also necessary to assess whether this precursor pool is totally metabolized to form the transmitter. The uniformity of the metabolic fate 457 E. COSTA ofthisimmediate precursor can be ascertained by comparing the turnover rate of this precursor to that of the transmitter. Table 11 lists the nonisotopic methods that can be used to measure turnover rate ofbrain 5-HT and tissue NE 5 3 . Allare based on the assumption that the various agents used to perturb the steady-state (MAO inhibitors, cx-methyltyrosine and probenecid) at the massive doses used in these experiments exert only one pharmacological action. This assumption is, howevcr, rather unrealistic. Therefore, we must consider that these methods give, at best, only an indication ofthe turnover rate. In order to reduce the probability of error, it is advisable to estimate turnover rate using at least two methods in order to consolidate the indicative value of these methods. Table 11 . Nonisotopic methods to measure turnover rate of brain monoamines Although a change in turnover rate elicited by drugs can not be readily interpreted in terms of the molecular mechanism involved, measurement of turnover rates may still be useful to localize the possible anatomical site of drug action. Moreover, when drugs do not change steady state concentrations of the transmitter, estimates of transmitter turnover rate are of value for identifying the chemical nature ofthe transmitter involved in a given drug action. However, when one wishes to localize a pharmacological response to a certain brain area using as a criterion the change in transmitter turnover rate, one should ascertain that this relationship is valid foranurober of doses. In other words, a relationship can be proposed only if the dose 458 response relationships between the two end points, pharmacological and turnover rate measurement, are similar. In Table 12 I illustrate such a study for ( + )-amphetamine, its stereo isomer, cocaine and aminorex. The data shown includes the most significant points of a dose response curve carried out with a wide dose range. It can be seen that for the drugs selected there is a remarkable correlation between the dose increasing motor activity and that accelerating the turnover rate of striatal DM. The turnover rate of telencephalic NE is not changed by the effective doses to increase motor activity. Hence, contrary to accepted opinion, Table 12 shows that ( + )-amphetamine and some chemically related compounds increase motor Rats (5 pcr group) received I mc kg· 1 i.v. of 3,5--'H tyrosine and 10 minutes later either saline or the drug listed in the Table; they were killed 15 minutes after the drug injection. Motor activity was measured during 15 minutcs after drug injection. Steady state concentrations of NE and DM were not changed by the drugs du ring 15 minutes. At this time, the S.A. of tissue tyrosinc was greater than that of either of the amines. activity when given in doses that change neither the steady state concentrations nor turnover rate of telencephalic NE. The data show that doses of the drugs that increase motor activity also increase the turnover rate of striatal DM although they do not affect the steady state concentrations of this amine. This finding exemplifies the utility ofturnover rate measurements to characterize the site of drug action.
(ii) M odifications of transmitter turnover rat es related to the rate of neuronal firing A characteristic property of the anticonvulsant diphenylhydantoin isthat 459 E. COSTA of lowering post-tetanic potentiation (PTP) in a number of preparations. We have studied the action of diphenylhydantoin in thc frog sympathctic ganglia. Since the concentration of diphenylhydantoin reducing PTP does not modify the response to single shocks, it may be inferred that diphcnylhydantoin reduces the release of transmitter elicited by nerve impulses. Recent reports 18 • 19 have indicated that the cerebellum is a sitc of action for diphenylhydantoin. This drug would increase the rate of firing of Purkinje cells which convey an important inhibitory input to the neurons they innervate. Stimulation of adrenergic cell bodies in /ocus caeruleus inhibits discharge rates of Purkin je cells 55 . The question then was: does diphcnylhydantoin decrease this noradrenergic control because it prevents thc release of transmitter from noradrenergic terminals? To answer this qucstion, we studied tbe effect of diphenylhydantoin on the turnover rate of ccrebellar NE in rats kept at 20oc and 4°C. The data shown in Table 13 indicate that the fractional rate constant for cerebellar NE is increased by cold exposure and that this effect is completely prevented by diphenylhydantoin. Diazepam, an anticonvulsant chemically related to diphenylhydantoin which also reduces PTP in thc frog sympathetic ganglia, seems to decrease the acceleration of ccrebellar NE turnovcr rate elicited by cold exposure. One could speculate that by synergizing the effccts of NE on the presynaptic regulatory receptor (Figure 1 ) both diazepam and diphenylhydantoin reduce postsynaptic potentiation and the turnover of NE in cerebellum. At this time, this is only a working hypothesis which I am presenting for your consideration as an examplc of thc questions that can be asked when concepts of neurochemistry are applied to models for drug screening.
